EROAD Ltd
NZX:ERD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
EROAD Ltd
NZX:ERD
|
NZ |
|
Medistim ASA
OSE:MEDI
|
NO |
|
A
|
Aptamer Group PLC
LSE:APTA
|
UK |
|
So-Young International Inc
NASDAQ:SY
|
CN |
|
Secos Group Ltd
ASX:SES
|
AU |
|
B
|
Bellavista Resources Ltd
ASX:BVR
|
AU |
|
Guardant Health Inc
NASDAQ:GH
|
US |
|
F
|
Figene Capital SA
WSE:FIG
|
PL |
|
Heroux Devtek Inc
TSX:HRX
|
CA |
|
Braze Inc
NASDAQ:BRZE
|
US |
Wall Street
Price Targets
ERD Price Targets Summary
EROAD Ltd
According to Wall Street analysts, the average 1-year price target for
ERD
is 1.97 NZD
with a low forecast of 1.21 NZD and a high forecast of 2.94 NZD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is ERD's stock price target?
Price Target
1.97
NZD
According to Wall Street analysts, the average 1-year price target for
ERD
is 1.97 NZD
with a low forecast of 1.21 NZD and a high forecast of 2.94 NZD.
What is EROAD Ltd's Revenue forecast?
Projected CAGR
4%
For the last 11 years the
compound annual growth rate for
EROAD Ltd's revenue is
31%.
The projected
CAGR
for the next 3 years is
4%.
What is EROAD Ltd's Operating Income forecast?
Projected CAGR
45%
For the last 11 years the
compound annual growth rate for
EROAD Ltd's operating income is
17%.
The projected
CAGR
for the next 3 years is
45%.
What is EROAD Ltd's Net Income forecast?
Projected CAGR
133%
For the last 11 years the
compound annual growth rate for
EROAD Ltd's net income is
-7%.
The projected
CAGR
for the next 3 years is
133%.
